- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Ramsey Today
By the People, for the People
Segall Bryant & Hamill LLC Reduces Stake in ADMA Biologics
Institutional investor cuts position in biotechnology company by 23.6% in Q3
Published on Mar. 6, 2026
Got story updates? Submit your updates here. ›
Segall Bryant & Hamill LLC, an institutional investor, reduced its stake in ADMA Biologics Inc. (NASDAQ:ADMA) by 23.6% in the third quarter of 2026, according to a recent SEC filing. The firm now owns 212,167 shares of the biotechnology company's stock, down from 277,733 shares held previously.
Why it matters
ADMA Biologics is a biopharmaceutical company focused on developing and commercializing specialty plasma-derived biologics. Institutional investors closely monitor changes in ownership stakes, as they can signal shifts in market sentiment or changes in a company's fundamentals.
The details
Segall Bryant & Hamill, an investment management firm, sold 65,566 shares of ADMA Biologics in the third quarter. The firm now owns approximately 0.09% of ADMA's outstanding shares, down from 0.12% previously. Other major institutional investors in ADMA Biologics include Westfield Capital Management, Thrivent Financial for Lutherans, and Franklin Resources.
- Segall Bryant & Hamill reduced its ADMA Biologics stake in the 3rd quarter of 2026.
The players
Segall Bryant & Hamill LLC
An institutional investment management firm that reduced its stake in ADMA Biologics.
ADMA Biologics Inc.
A biopharmaceutical company focused on developing and commercializing specialty plasma-derived biologics.
The takeaway
The reduction in Segall Bryant & Hamill's ADMA Biologics stake could signal a shift in market sentiment or changes in the company's fundamentals, which institutional investors closely monitor. However, ADMA Biologics remains backed by other major institutional investors, indicating ongoing confidence in the company's prospects.
